Navigation Links
Nanoparticles carry cancer-killing drugs into tumor cells

A missing receptor molecule contributes to the growth of tumors in human ovaries. This surprisingly evident connection has now been proven by a team at the Medical University of Vienna, who published their data in the science journal Molecular Cancer Research. The team, who is supported by funding from the Austrian Science Fund FWF, also discovered the possible genetic reason why the receptor molecule, which is an important factor in regulating cell growth, is missing.

In healthy tissue, cells grow and divide - this is also true of cancerous tumors. The difference between the two lies in the regulation, which functions well in healthy tissue, but not in tumors. An important mechanism of this regulation is programmed cell death, known as apoptosis. It causes the controlled death of single cells, if this is to the advantage of the whole organism. If this process of self-protection does not work then the destructive cells can proliferate uncontrollably.

Signal Without Effect
Prof. Michael Krainer and his team from the Medical University of Vienna have now been able to prove that programmed cell death does not function in cells of certain tumors in the ovaries. Not because the starting signal is missing, but because this signal cannot be received by the cell.

This finding, published today in the American science journal Molecular Cancer Research, shows that these cells lack a receptor molecule called DR4. DR4 is responsible for receiving the signal molecule TRAIL, which initiates apoptosis in these cells.

Prof. Krainer explains: "To begin with it was not evident what was missing in the signal transmission. The signal or the receptor molecule? To answer this question, we examined ten different ovarian cancer cell lines. In doing this we found out that 40% of these specimens contained none or only a few DR4 receptor molecules." It was proven in further tests that these cells react particularly badly to TRAIL. This proves that the missi ng receptor and not the missing signal can contribute significantly to tumor growth.

Silenced Genes
Further tests proved why there was such a small number of receptors. Prof. Krainer: "There can be two reasons for the loss of a receptor molecule like DR4. Firstly, the responsible gene could have been lost or damaged. Secondly, this gene could have been modified in a way which would prevent it from functioning." It was exactly the latter. Prof. Krainer and his team ascertained that in 75% of the specimens which contained only a few DR4 receptors the responsible gene was modified. Some components of this gene were modified by attaching methyl groups. Methylation is indeed a common way in which cells silence genes, but in the affected tumor cells, it obviously happens at the wrong time.

To conclude their research, Prof. Krainer and his colleagues retested their findings: Their results were confirmed by testing 36 different tumor tissues taken directly from patients. In comparison, these cells represent the real causes of disease much better than cell cultures commonly used for experimental research. It was determined that in 20% of the tissues examined the gene responsible for DR4 was methylated to a higher degree and DR4 was missing.

This research supported by funding from the Austrian Science Fund, FWF, paves the way for future therapy through the important discovery that the methylation of the gene for DR4 can contribute to the formation of tumors. These therapies could manipulate the malfunctioning signal transfer system, DR4-TRAIL, to make cancer cells return to the originally programmed cell death.

Image and text will be available online from Wednesday, 15th June 2005, 09.00 a.m. MEZ onwards:



Related biology news :

1. DNA Molecules Used To Assemble Nanoparticles
2. Imaging Lymph Nodes with Nanoparticles
3. Probing The Promise And Perils Of Nanoparticles
4. Nanoparticles offer new hope for detection and treatment
5. Nanoparticles, nanoshells, nanotubes: How tiny specks may provide powerful tools against cancer
6. Nanoparticles for delivery of prostate cancer treatment
7. Nanoparticles can track cells deep within living organisms
8. Cancer tip -- Nanoparticles can damage DNA, increase cancer risk
9. Performing monkeys in Asia carry viruses that could jump species to humans
10. Molecular machine may lead to new drugs to combat human diseases
11. Researchers identify target for cancer drugs
Post Your Comments:

(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
(Date:11/25/2015)... 25, 2015 The Global ... a professional and in-depth study on the current ... (Logo: ) , The ... including definitions, classifications, applications and industry chain structure. ... international markets including development trends, competitive landscape analysis, ...
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... Nov. 24, 2015  Clintrax Global, Inc., a worldwide provider of ... , today announced that the company has set a new quarterly ... quarter on quarter growth posted for Q3 of 2014 to Q3 ... Mexico , with the establishment of an ... --> United Kingdom and ...
Breaking Biology Technology: